ProxyMiner / Company

GILEAD SCIENCES, INC.GILD

Latest proxy: 2026 · view on SEC ↗ · CIK 0000882095

CEO total pay

$28,437,198

Daniel P. O’Day · 2025

Say on pay

Not disclosed

Use Ask for the underlying narrative

CEO pay ratio

CD&A

Not in CD&A

Median employee: $238,979

Compensation committee

CD&A

Compensation and Talent Committee

Per the latest proxy

Filings indexed: 2 · 2026 · 2025

Executive pay

What did they pay them?

From the Summary Compensation Table. Pay mix and YoY are computed from these rows.

ExecutiveRoleTotalYoYPay mixSalaryStockCash incentiveOther
Daniel P. O’Day2025 compensation
Chairman and Chief Executive Officer
$28,437,198 20%
86% at-risk
$1,795,192$15,238,402$4,848,120$2,055,424
Andrew D. Dickinson2025 compensation
Chief Financial Officer
$8,765,616 8%
86% at-risk
$1,116,654$4,321,741$1,956,266$70,979
Dietmar Berger, M.D., Ph.D.2025 compensation
Chief Medical Officer
$13,922,878
91% at-risk
$969,231$6,999,758$1,603,594$350,252
Johanna Mercier2025 compensation
Chief Commercial and Corporate Affairs Officer
$9,300,643 8%
86% at-risk
$1,182,269$4,564,517$2,150,901$102,980
Deborah H. Telman2025 compensation
Former Executive Vice President, Corporate Affairs and General Counsel
$5,004,669 18%
79% at-risk
$977,334$3,071,792$55,478

Pay mix: base cash incentive equity other

CD&A excerpt

Compensation discussion & analysis

Opening passage of the loaded filing's CD&A. Use Ask below to query the full text with citations.

This Compensation Discussion and Analysis provides an overview of the components of our executive compensation program and the 2025 decisions of the Compensation and Talent Committee of our Board (our “Compensation and Talent Committee” or “Committee”) for our 2025 Named Executive Officers (or “NEOs”), who are set forth below. As of December 31, 2025, Gilead had four executive officers. Daniel P. O’Day Andrew D. Dickinson Johanna Mercier Dietmar Berger, M.D., PH.D. Deborah H. Telman Chairman and Chief Executive Officer (“Chief Executive Officer” or “CEO”) Chief Financial Officer Chief Commercial and Corporate Affairs Officer Chief Medical Officer(1) Former Executive Vice President, Corporate Affairs and General Counsel(2) (1) Dr. Berger commenced employment as Gilead’s Chief Medical Officer on January 2, 2025. (2) As discussed below, Ms. Telman ceased to serve as Gilead’s Executive Vice President, Corporate Affairs and General Counsel on December 5, 2025, and her employment with the company terminated without cause later in December. 2025 Business Highlights In 2025, Gilead delivered strong financial and strategic results that directly reflect continued execution against our long-t

Read the full CD&A on SEC.gov ↗

Peer comparison

Who they benchmark against

Click any peer to jump to their proxy. Peers we haven't ingested yet kick off an import on click.

Governance

Policy guardrails

  • hedging

    prohibited

    Insider Trading, Hedging and Pledging Prohibitions

  • pledging

    prohibited

    Insider Trading, Hedging and Pledging Prohibitions

  • clawback

    present

    Recoupment Policy, our second clawback policy, which has been in place for several years, the Compensation and Talent Committee has authority to recoup cash incentive payments and equity awards (which includes time-based

  • stock ownership guidelines

    present

    stock ownership guidelines require our executive officers to maintain a substantial ownership interest in Gilead

  • change in control

    A “change in control of Gilead” will be deemed to occur upon

    A “change in control of Gilead” will be deemed to occur upon

  • compensation consultant

    independent

    independent compensation consultant

  • compensation committee

    Compensation and Talent Committee

    Compensation and Talent Committee

Performance markers

Metric facts

  • revenue

    $28.4 billion

    of performance achievement: ► The vesting requirement for the TSR tranche was tied to our relative TSR for the performance period from March 1, 2023 through December 31, 2025, compared to the TSR of the companies compris

  • operating income

    and adjusted operating income performance goals that excluded Veklury revenue, consistent with the approach used in 2021 through 2024. The 2025 approved adjusted net product revenue and adjusted operating income targets,

  • ceo pay ratio

    the amounts reported below. Factors that could affect such amounts include the timing during the year of the event, our stock price, target amounts payable under annual and long-term incentive arrangements that are in pl

  • median employee compensation

    $238,979

    We then calculated annual total compensation for the median compensation employee using the same methodology we use for our Named Executive Officers as set forth in the Summary Compensation Table. The 2025 annual total c

Ask

Anything about GILEAD SCIENCES, INC.’s 2026 proxy

Answers are grounded in the loaded filing and cite specific artifacts. Bring your own free Google AI Studio key.

Loading the Ask interface…